Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 17, 2021 - Issue 6
Submit an article Journal homepage
183
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Safety and pharmacokinetic interaction between fotagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin in healthy subjects

Yanhua Dinga Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, Jilin, ChinaView further author information
,
Hong Zhanga Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, Jilin, ChinaView further author information
,
Cuiyun Lia Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, Jilin, ChinaORCID Iconhttps://orcid.org/0000-0002-6306-2394View further author information
ORCID Icon,
WenBo Zhenga Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, Jilin, ChinaView further author information
,
Meng Wanga Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, Jilin, ChinaView further author information
,
Ying Lib Shenzhen Salubris Pharmaceuticals Co Ltd, Shenzhen, GuangdongChinaView further author information
,
HaiGang Sunb Shenzhen Salubris Pharmaceuticals Co Ltd, Shenzhen, GuangdongChinaView further author information
&
Min Wua Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, Jilin, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 725-731 | Received 28 Feb 2021, Accepted 07 Apr 2021, Published online: 26 Apr 2021

References

  • Tuomi T, Santoro N, Caprio S, et al. The many faces of diabetes: a disease with increasing heterogeneity. Lancet. 2014;383(9922):1084–1094.
  • McKennon SA, Campbell RK. The physiology of incretin hormones and the basis for DPP-4 inhibitors. Diabetes Educ. 2007;33(1):55–66.
  • Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitusprogressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281(21):2005–2012.
  • Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2009;32(1):193–203.
  • Ahren B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep. 2003;3(5):365–372.
  • Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26(10):2929–2940.
  • Sorbera LA, Revel L, Castaner J. P32/98: antidiabetic dipeptidylpeptidase IV inhibitor. Drugs Future. 2001;26(9):859–864.
  • Villhauer EB, Coppola GM, Hughes TE. DPP-IV inhibition and therapeutic potential. Annu Rep Med Chem. 2001;36:191–200.
  • Ndefo UA, Okoli O, Erowele G. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus. Am J Health Syst Pharm. 2014;71(2):103–109.
  • Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates -cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003;52(3):741–750.
  • Goodarzi MO, Bryer-Ash M. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab. 2005;7(6):654–665.
  • Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs. 2003;63(18):1879–1894.
  • Sonne DP, Hemmingsen B. Comment on American Diabetes Association. Standards of medical care in diabetes- 2017. Diabetes Care. 2017;40(7):E92–E93.
  • Marathe PH, Gao HX, Close KL. American Diabetes Association standards of medical care in diabetes. J Diabetes. 2017;9(4):320–324.
  • Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type2 diabetes. Lancet. 2006;368(9548):1696–1705.
  • Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitors itagliptinas monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632–2637.
  • Yl H, Sabo R, Picard F, et al. Lack of pharmacokinetic interaction between vildagliptin and metformin in patients with type 2 diabetes. Clin Pharmacol Ther. 2006;79(2):62.
  • Shin D, Cho YM, Lee SH, et al. Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects. Clin Drug Investig. 2014;34(6):383–393.
  • Libman IM, Miller KM, DiMeglio LA, et al. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA. 2015;314(21):2241–2250.
  • McCreight LJ, Stage TB, Connelly P, et al. Pharmacokinetics of metformin in patients with gastrointestinal intolerance. Diabetes Obes Metab. 2018;20(7):1593–1601.
  • Corte CMD, Ciaramella V, Mauro CD, et al. Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells. Oncotarget. 2016;7(4):4265–4278.
  • Kulkarni AS, Brutsaert EF, Anghel V, et al. Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults. Aging Cell. 2018;17(2):e12723. Epub 2018 Jan 31.
  • Salvatore T, Pafundi PC, Morgillo F, et al. Metformin: An old drug against old age and associated morbidities. Diabetes Res Clin Pract. 2020Feb;160:108025.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.